The article discusses the effectiveness of technology investments in adding value to clinical developments in the drug industry. It examines the benefits of the electronic data capture (EDC) system that was introduced by Phased Forward. The opinion of Susan J. Ward, a former senior executive officer at Wyeth, on the value of research & development (R&D) in the pharmaceutical sector is also cited.